Impact of concomitant use of renin–angiotensin system inhibitors on survival in patients with pancreatic ductal adenocarcinoma: a systematic review and meta-analysis
Therapeutic Advances in Medical Oncology
Published online on March 21, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Pancreatic ductal adenocarcinoma (PDAC) is characterized by poor prognosis and limited therapeutic options, particularly in the metastatic setting. Novel strategies to overcome treatment resistance are highly anticipated and may potentially ...
Background:Pancreatic ductal adenocarcinoma (PDAC) is characterized by poor prognosis and limited therapeutic options, particularly in the metastatic setting. Novel strategies to overcome treatment resistance are highly anticipated and may potentially ...